Israel's Brainsway has finally locked in a commercial partner to mount a large-scale U.S. commercial effort for its FDA-approved device to treat depression, but the company is keeping details to itself.
Brainsway surged on the Tel-Aviv Stock Exchange today after the company announced positive results from a study of its transcranial magnetic stimulation (TMS) treatment in severely depressed patients.
Israel's Brainsway is dialing back its IPO expectations. It has filed more documents with the SEC saying it will offer about 1.8 million shares for between $10 and $12 per share. The filing comes
Israel's Brainsway has filed its prospectus with the SEC to raise $30 million on NASDAQ. The company says in the filing that it will use approximately 70 to 75 percent of the net proceeds for